Role of serum cystatin C in the prediction of acute kidney injury following pediatric cardiac surgeries: A single center experience.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
09 Dec 2022
09 Dec 2022
Historique:
entrez:
10
1
2023
pubmed:
11
1
2023
medline:
13
1
2023
Statut:
ppublish
Résumé
Intense contemporary research is directed towards validating novel biomarkers to predict acute kidney injury (AKI) in children undergoing cardiothoracic surgeries. We aimed to evaluate the role of cystatin C in early prediction of AKI following cardiac surgery in children with congenital heart disease. Prospective observational cohort study was conducted on 40 children with congenital heart disease undergoing cardiac surgery. 40 healthy children with matched age and sex were enrolled as a control group. Children were subjected to physical examination, routine blood tests, echocardiography, and measurement of plasma cystatin C level on different occasions. The median age of the patients was 3.65 years, a range from 1 to 5 years with no significant difference regarding the age and sex of cases and control groups. The mean serum cystatin C level in patients was 0.75 ± 0.15, 1.35 ± 0.34 and 1.21 ± 0.38 mg/dL (preoperative, at 6 h and at 24 h postoperative, respectively) with statistically significant difference P < .05. 30% of the patients developed postoperative AKI with significantly higher serum cystatin C at 6 hours postoperative >1.33 mg/dL compared to preoperative level p P < .05. Serum cystatin C level was positively correlated with cardiac bypass time, ischemic time and length of hospital stay at 6 hours postoperative. Serum cystatin C is a sensitive marker for early detection of AKI following cardiac surgery in children with congenital heart disease and it was positively correlated with cardiac bypass time, ischemic time and length of hospital stay.
Identifiants
pubmed: 36626503
doi: 10.1097/MD.0000000000031938
pii: 00005792-202212090-00017
pmc: PMC9750614
doi:
Substances chimiques
Biomarkers
0
Creatinine
AYI8EX34EU
Cystatin C
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31938Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
J Thorac Cardiovasc Surg. 2012 Feb;143(2):495-502
pubmed: 22050987
Clin J Am Soc Nephrol. 2010 Sep;5(9):1552-7
pubmed: 20538834
J Am Soc Nephrol. 2018 May;29(5):1549-1556
pubmed: 29472416
Am J Nephrol. 2000 Mar-Apr;20(2):97-102
pubmed: 10773608
Crit Care. 2007;11(2):R31
pubmed: 17331245
Am J Kidney Dis. 2012 Dec;60(6):922-9
pubmed: 22809763
Am J Kidney Dis. 2002 Aug;40(2):221-6
pubmed: 12148093
Circulation. 2010 May 18;121(19):2117-22
pubmed: 20439784
Crit Care. 2004 Aug;8(4):R204-12
pubmed: 15312219
J Am Soc Nephrol. 2012 May;23(5):905-14
pubmed: 22383693
Clin J Am Soc Nephrol. 2009 Nov;4(11):1832-43
pubmed: 19820136
BMC Nephrol. 2017 Apr 3;18(1):120
pubmed: 28372557
Clin Biochem. 2007 Mar;40(5-6):383-91
pubmed: 17316593
JAMA Pediatr. 2015 Jun;169(6):583-91
pubmed: 25844892
Kidney Int. 2008 Oct;74(8):1059-69
pubmed: 18650797
J Intensive Care. 2017 Jul 20;5:49
pubmed: 28729908
Nephrol Dial Transplant. 2013 Feb;28(2):254-73
pubmed: 23115326
J Am Soc Nephrol. 2006 Jan;17(1):254-61
pubmed: 16267155
Kidney Int. 2011 Sep;80(6):655-62
pubmed: 21525851
Clin J Am Soc Nephrol. 2010 Aug;5(8):1373-9
pubmed: 20522534
Kidney Int. 2004 Sep;66(3):1115-22
pubmed: 15327406
Clin J Am Soc Nephrol. 2013 Jun;8(6):1034-42
pubmed: 23471130
J Crit Care. 2013 Aug;28(4):389-96
pubmed: 23743540